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The aim of this phase I/II study was to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities of chronic oral
etoposide given on days 1–10 followed by rescue with subcutaneous (s.c.) granulocyte-macrophage colony-stimulating factor (GM-
CSF) on days 12–19 as second-line chemotherapy in platinum-pretreated patients (pts) with advanced ovarian carcinoma. Cohorts
of three to six pts were treated with doses of oral etoposide from 750mgm
 2cycle
 1 escalated to 1250mgm
 2cycle
 1 over 10
days, every 3 weeks. Subcutanous GM-CSF, 400mg once daily, days 12–19, was added if dose-limiting granulocytopenia was
encountered. In total, 18 pts with a median Karnofsky index of 80% (range, 70–100%) and a median time elapsed since the last
platinum dose of 10 months (range, 1–24 months), 30% of whom showed visceral metastases, were treated at four dose levels
(DLs) of oral etoposide on days 1–10 of each cycle as follows: DL 1, 750mgm
 2cycle
 1, without GM-CSF, three pts; DL 2,
1000mgm
 2cycle
 1, without GM-CSF, three pts; DL 3, 1000mgm
 2cycle
 1, with GM-CSF, six pts; and DL 4,
1250mgm
 2cycle
 1, with GM-CSF, six pts. All pts were assessable for toxicity and 16 pts for response. Dose-limiting toxicity
(DLT) was reached at DL 4 by three of six pts, showing World Health Organization (WHO) toxicity grade 4. One patient died from
gram-negative sepsis associated with granulocytopenia grade 4. Two more pts developed uncomplicated granulocytopenia grade 4.
Thus, we recommend that DL 3 can be used for further phase II evaluation (i.e. oral etoposide 1000mgm
 2cycle
 1, days 1–10,
followed by s.c. GM-CSF 400mg, days 12–19). The clinical complete or partial responses in each patient cohort were: DL 1, one of
three pts; DL 2, one of three pts; DL 3, three of five pts; and DL 4, two of five pts. In conclusion, in this phase I/II study, we defined the
MTD and the dose recommended for the therapy with oral etoposide given over 10 days followed by s.c. GM-CSF in platinum-
pretreated patients with advanced ovarian cancer. Our data demonstrate encouraging activity of this regimen and strongly support its
further investigation in a phase II study.
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Optimal treatment for patients with resistant ovarian cancer has
not been standardised to date. The main goals of salvage therapy in
these patients are maximisation of their disease-free survival,
performance status, and quality of life, depending on the patient’s
cumulative toxicities due to previous chemotherapy (Salom et al,
2002). A variety of treatment options are available for resistant
ovarian cancer, including topotecan, pegylated liposomal doxo-
rubicin, gemcitabine, and etoposide.
Until today, etoposide has remained the only substance available
as an oral formulation, allowing for outpatient treatment, thereby
markedly increasing the convenience for the patient. Etoposide is a
cell-cycle, late S- or early G2-phase-specific cytotoxic agent that
inhibits topoisomerase II, which is responsible for the cytotoxic
activity of etoposide. Inhibition of topoisomerase II is rapidly
reversible when plasma levels of etoposide decline (Greco et al,
1991). Therefore, it was hypothesised that chronic oral adminis-
tration of etoposide may result in significant killing of tumour
cells. Clinical data have clearly demonstrated the superiority of the
delivery of etoposide in a multiple-day schedule compared with
delivery of a single dose every 3–4 weeks (Slevin et al, 1989).
In ovarian carcinoma, various schedules of peroral administra-
tion of etoposide exist that range from 3 to 21 consecutive days of
application per cycle, with single daily doses ranging from 25 to
200mgm
 2 and with treatment cycles lasting 2–4 weeks. These
schedules result in intended dose intensities ranging from 131 to
283mgm
 2 week
 1 (Maskens et al, 1981; Hillcoat et al, 1985;
Hansen et al, 1990; Garrow et al, 1992; Markman et al, 1992;
Marzola et al, 1993; De Wit et al, 1994; Hoskins and Swenerton,
1994; Seymour et al, 1994; Kavanagh et al, 1995; Yasumizu and
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sKato, 1995; Kuhn et al, 1996; Tuxen et al, 1997; Rose et al, 1998;
Alici et al, 2003). However, the optimal schedule of chronic oral
administration of etoposide is still to be defined.
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
given subcutaneously (s.c.) is known to reduce the incidence and
duration of severe granulocytopenia and to enhance the dose
intensity of cytotoxic therapy by stimulating the proliferation and
differentiation of haematopoietic progenitor cells as well as the
functional activity of effector cells (Font et al, 1999).
In this study, we administered GM-CSF s.c. after peroral
treatment with etoposide to overcome the dose-limiting myelo-
toxicity of etoposide and to increase the dose intensity per
treatment cycle, thereby increasing the response rate, which
ultimately would lead to a prolonged progression-free interval
and a shorter time to response.
The aim of this phase I/II study was to determine the maximum
tolerated dose (MTD) of oral etoposide given on days 1–10
followed by s.c. GM-CSF on days 12–19. These data could serve as
the basis for recommendations for future phase II trials in patients
with recurring ovarian cancer and/or patients with ovarian cancer
refractory to previous platinum-based treatment.
PATIENTS AND METHODS
Eligibility criteria
Women between the ages of 18 and less than 75 years with
histologically proven epithelial ovarian cancer and measurable
progressive disease or relapse were eligible for entry into this
phase I/II study. Patients must have received only one previous
chemotherapeutic regimen containing either cisplatin or carbo-
platin; previous additional treatment with a taxane also was
permitted. Further eligibility criteria included adequate bone
marrow function (platelets4100000ml
 1, haemoglobin410gdl
 1,
leucocytes43.500ml
 1), normal renal function (serum creatinineo
1.3mgdl
 1 and/or creatinine clearance460mlmin
 1), normal
liver function (transaminases o2  the normal value, bilirubin
o1.5gdl
 1), Karnofsky performance status X70%, and freedom
from other malignancies for 5 years or more (except successfully
treated basal cell and squamous cell carcinoma of the skin or
carcinoma in situ of the cervix). Patients were excluded if their
expected survival was less than 3 months, had an uncontrolled
systemic infection, had received an investigational drug within the
last 30 days, had received chemotherapy within 30 days of the first
cycle of etoposide, or had been pretreated with etoposide. Written
informed consent was obtained from all patients. The study was
carried out after having received approval of the hospital’s ethics
committee.
Treatment plan
Oral etoposide (Vepesid
s) 100mg capsules were given on days 1–
10 of each treatment cycle in two daily doses, divided equally, over
the 10-day period until the projected cumulative dose per cycle was
reached. GM-CSF 400mg (Leukomax
s) was administered s.c. over
eight consecutive days per cycle (days 12–19), preferably in the
evening.
Cycles were repeated every 3 weeks. The duration of treatment
was at least three cycles per patient, with an evaluation of the first
response planned after this period, and up to six cycles per patient.
Dose-escalation algorithm
A dose level (DL) was defined as a cohort of three patients who
received at least one cycle of the same DL of oral etoposide. The
projected DLs of oral etoposide started with 750mgm
 2cycle
 1
(without GM-CSF) and were increased in a stepwise manner by
250mgm
 2cycle
 1. At any given DL, an increase of oral etoposide
to the next DL was projected if none of the three patients showed a
dose-limiting toxicity (DLT), defined as grade 4 (G4) haemato-
toxicity and/or G3 or G4 nonhaematological toxicity during the
previous therapy cycle. If a DLT occurred in at least one of three
patients, three additional patients were treated with this dose level.
Maximum tolerated dose was reached when two of three patients
or two or more of six patients showed G4 haematotoxicity and/or
G3 or G4 nonhaematological toxicity. The DL at which fewer than
two of six patients showed a DLT represents the dose recom-
mended for further treatment. No individual intrapatient dose
escalation was planned.
Granulocyte-macrophage colony-stimulating factor 400mg s.c.
once daily on days 12–19 was added for all consecutive cycles in
patients who had experienced G4 granulocytopenia and, at all
further DLs once dose-limiting, that is, World Health Organization
(WHO) G4 granulocytopenia, had been encountered. Antiemetic
prophylaxis consisted of ondansetron 8mg b.i.d. and, if necessary,
the addition of dexamethasone t.i.d. 8mg perorally.
Termination of treatment after the completion of six therapy
cycles was planned. However, in cases of disease progression,
treatment was terminated after the third treatment course, the time
when patients underwent their first scheduled treatment evalua-
tion. Furthermore, treatment could be stopped at any time in case
of unacceptable toxicity or at the request of the patient.
In cases of G4 granulocytopenia or G4 thrombocytopenia, the
protocol required a dose reduction to the previous DL for all
further treatment. If the patients’ granulocytes and/or thrombo-
cytes did not meet entry criteria at the scheduled retreatment, a
delay in treatment of up to 3 weeks was permitted.
Pretreatment, response and follow-up evaluation
Within 21 days before the first dose of oral etoposide, baseline
disease was documented by radiologic imaging (chest X-ray,
computed tomography). Within 1 week before application of oral
etoposide, all patients underwent a physical examination, includ-
ing laboratory analyses (complete blood count, serum chemistry,
CA-125 analysis, urine analysis) and assessment of their medical
history. A physical examination, serum chemistries, and CA-125
analyses were repeated at each cycle, and a complete blood cell
count was obtained weekly. Radiologic reassessment (using the
same methodology used at baseline) was performed after the third
and sixth treatment cycles.
The evaluation of a patient’s response to oral etoposide was
based on WHO criteria (UICC, 1987). Patients had to have received
a minimum of three cycles of therapy to be eligible for the
evaluation of response. If there was clinical indication for early
progression of disease, however, an evaluation was performed
earlier. Assessment of serologic response was performed by serial
CA-125 measurements, defining a decrease of the CA-125 baseline
value of at least 50% as a clinical response.
For the definition of platinum responsiveness, patients were
considered truly platinum resistant if they relapsed within 6
months of completion of their first-line treatment with platinum-
containing therapy or showed disease progression during first-line
treatment with platinum-containing therapy.
All patients who had received at least one cycle of oral etoposide
were included in the safety analyses. Patient monitoring and
scoring of toxicity were performed weekly according to the WHO
Toxicity Criteria (WHO, 1979). For determination of the DLT, the
occurrence of WHO G4 granulocytopenia or thrombocytopenia or
WHO G3 or G4 nonhaematological toxicities were assessed and
considered.
Statistical analysis
Time to progression (i.e. time between the start of treatment and
the first objective evidence of tumour progression, or the time to
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scensoring) was estimated by the Kaplan–Meier method. Since
previous trials did not specify body surface areas, we based
comparisons of dose intensities on a standard of 1.75m
2 body
surface area, which corresponded to a woman with an average
weight of 68kg and an average height of 165cm.
In calculations that involved treatment duration, 3 weeks was
considered 100%, with 1 week corresponding to 33.3%.
In the analyses of the influence of a specific line of oral
etoposide on response rate of oral etoposide (see Table 7), we
compared the response rates of patients treated in first-line to
response rates of patients treated in second-line to response rates
of patients treated in third-line, and to response rates of patients
treated in fifth-line treatment. Thereby, the group termed ‘third-
line’ therapy consisted of studies administering oral etoposide in
mixed lines (either third-line, or second/third- or fourth-line, or
third/fourth-line or second/third-line treatment).
RESULTS
A total of 18 patients were entered into this phase I/II study. Their
characteristics are shown in Table 1. In accordance with protocol
requirements, all patients received first-line pretreatment with a
platinum-based regimen and 30% also received a taxane.
Dose escalation
Patients were entered at four DLs (Table 2), escalating the dose of
oral etoposide from 750mgm
 2cycle
 1 at DL 1 to 1250mgm
 2
cycle
 1 at DL 4. We enrolled three patients at DL 1(750mgm
 2
cycle
 1 without GM-CSF), three patients at DL 2 (1000mgm
 2
cycle
 1 without GM-CSF), six at DL 3 (1000mgm
 2cycle
 1 with
GM-CSF), and six at DL 4 (1250mgm
 2cycle
 1 with GM-CSF).
No DLT was observed in the first three patients treated at DL 1.
One of three patients treated at DL 2 experienced WHO G4
granulocytopenia. In conformity with the protocol, we therefore
added GM-CSF to the consecutive DL 3. At DL 3, none of three
patients showed haematological toxicity G4 or any other
nonhaematological toxicity G3/G4.Thus, we increased the dose of
oral etoposide to 1250mgm
 2cyle
 1 in combination with GM-
CSF. One patient of three treated at DL 4 developed granulocy-
topenia G4 and an associated fatal gram-negative sepsis. Conse-
quently, three additional patients were entered at DL 4, totaling six
patients at this DL. One of these additional patients developed
granulocytopenia G4 associated with a G3 infection including fever
and G2 mucositis, necessitating hospitalisation and treatment with
broad-spectrum antibiotics. The patient’s recovery was uncompli-
cated, and treatment could be resumed following a delay of only 1
week and with a reduced dose of oral etoposide. A third patient at
DL 4 developed G4 granulocytopenia and had to be given
antibiotics on the ward in response to G2 phlebitis. Overall, at
DL 4, three of six patients experienced G4 granulocytopenia that
demanded antibiotic treatment on the ward and prohibited a
further escalation in dose. Subsequently, three additional patients
were entered at DL 3. Overall, only one of six patients at DL 3
developed G4 granulocytopenia, which was associated with fungal
esophagitis and necessitated antimicrobial treatment on the ward.
We conclude that, for oral etoposide, the DL 3 dosage of
1000mgm
 2cycle
 1 on days 1–10 plus GM-CSF s.c. 400mg daily
on days 12–19, repeated every 3 weeks, should be recommended
for further phase II studies.
Toxicities per patient over all cycles
Haematological and nonhaematological toxicities over all the
cycles administered to the 18 patients who entered our study are
summarised in Tables 3 and 4. At DL 3, that is, at the dose we
recommend for phase II studies, we observed G3 or G4
granulocytopenia in three of six patients. The median granulocyte
nadirs during the first cycles were 1600ml
 1 at DL 1, 600ml
 1 at DL
2, 800ml
 1 at DL 3, and 300ml
 1 at DL 4. In contrast, the median
nadirs of granulocytes from cycles 2–6 were 1900ml
 1 at DL 1,
1150ml
 1 at DL 2, 1200ml
 1 at DL 3, and 2200ml
 1 at DL 4. If GM-
CSF was administered, recovery from granulocytopenia occurred 6
days earlier, that is, after a median of 14 days (range, 6–29 days),
whereas granulocytopenia occurred after a median of 20 days
(range, 5–33 days) without the addition of GM-CSF. Overall, no
cumulative toxicity was observed. Owing to an allergy to GM-CSF
in one patient, granulocyte colony-stimulating factor was used for
her further treatment. One patient with G4 thrombocytopenia
required a one-time platelet transfusion. Severe nonhaematological
Table 1 Patient characteristics
Number of patients (n)1 8
Age (years) median (range) 58 (43–72)
Sites of metastases
One site 9
Two sites 8
Three sites 1
Tumour grade (n)
Well differentiated 1
Moderately differentiated 5
Poorly or undifferentiated 12
Performance status according to Karnofsky (%)
70 1
80 8
90 4
100 4
NE 1
Time (months) elapsing from last platinum dose to start of oral
etoposide
Median (range) 10 (1–24)
Previous chemotherapy as first-line therapy (no. of patients)
Platinum based 18
Cyclophosphamide 9
Epidoxorubicin 1
Paclitaxel 5
Response to previous platinum (no. of patients)
Platinum sensitive 9
Platinum resistant 9
NE¼not evaluable.
Table 2 Number of patients with World Health Organization grade 4
toxicities, by dose level, at the first treatment cycle
Dose level
12 3 4
Patients treated (number) 3 3 6 6
Oral etoposide (cumulative dose: mgm
 2cycle
 1) 750 1000 1000 1250
GM-CSF    ++
Toxicity grade 4
Granulocytopenia 0 1 1 3
Thrombocytopenia 0 0 0 1
Sepsis (death) 0 0 0 1
GM-CSF, granulocyte-macrophage colony-stimulating factor;  GM-CSF¼without
GM-CSF; + GM-CSF¼with GM-CSF.
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stoxicity was restricted to colitis, which presented with G3 intensity
in one patient and with G4 intensity accompanied by eosinophilic
infiltration in another patient. All other toxicities were negligible
and manageable.
Dose-intensity analysis
A total of 93 cycles (median, 6; range, 1–6) were administered in
18 patients. A mean of 98% (range, 83–100%) of the planned dose
of oral etoposide could be administered, with a mean treatment
duration of 116% (range, 100–140%; 100% corresponding to 3
weeks). In 12 of 18 patients, the duration of treatment had to be
extended because of granulocytopenia in nine patients (four
patients experienced a delay of 1 week, one patient for 2 weeks,
and one for 3 weeks, and in three patients for an overall of 6 weeks
each), G2 phlebitis in one patient, G2 mycotic esophageal infection
in another patient, and G4 eosinophilic colitis in one other patient.
A median effective dose intensity of 234mgm
 2 week
 1 at DL 1, of
238mgm
 2 week
 1 at DL 2, of 272mgm
 2 week
 1 at DL 3, and of
417mgm
 2 week
 1 at DL 4 was reached. Overall, an effective
median dose intensity of 292mgm
 2 week
 1 for all DLs was
achieved.
Response to treatment and progression-free interval
In total, 16 of 18 patients were evaluable for response. One patient
died after the first cycle at DL 4 of gram-negative sepsis associated
with G4 granulocytopenia. In another patient, treatment was
stopped at the request of the patient after the second treatment
cycle at DL 3, and could therefore not be evaluated for response.
Clinical complete or partial responses in each patient cohort were
observed at DL 1 in one of three patients, at DL 2 in one of three
patients, at DL 3 in three of five patients, and at DL 4 in two of five
patients. Overall, four patients reached a complete response, three
patients reached a partial response, seven patients had no change,
and two patients showed disease progression. Seven (44%) patients
of 16 patients objectively responded to oral etoposide as second-
line therapy. The two patients with tumour progression belonged
to the patient cohorts of DL 2 and DL 4.
Six of nine platinum-sensitive patients responded to etoposide
as compared with only one of seven platinum-resistant patients
(Table 5).
Two of three patients, whose response to pretreatment with a
taxane was evaluable, responded to oral etoposide as second-line
therapy, whereas five of 12 patients without taxane pretreatment
did so. When the evaluation of tumour response was based on the
WHO tumour response criteria, the median time to response was 2
months and decreased to 1.5 months when response criteria
included levels of serological CA-125 tumour marker.
The median progression-free interval for all patients was 7
months (range, 1þ to 9 months).
In accordance with the protocol, treatment was discontinued in
seven patients after they had completed six treatment cycles
without disease progression, in eight patients because of tumour
progression, in two patients by request of the patient, and in one
patient because of death due to sepsis.
DISCUSSION
In this study, we achieved an increase in dose intensity of
etoposide by using GM-CSF, which advanced by 6 days, the
granulocyte nadir following etoposide.
In previous trials, several groups (Seymour et al, 1994;
Kavanagh et al, 1995; Tuxen et al, 1997; Rose et al, 1998)
succeeded in intensifying the dose of etoposide administered
without severe haematotoxicity by escalating stipulated doses on
an individual basis. In contrast, Garrow et al (1992) and De Wit
et al (1994), who did not make such intraindividual increases in
etoposide doses, achieved only the lower median dose intensities
of etoposide. We did not design our study to consider individual
intrapatient escalation of dose. However, with the use of GM-CSF
at DL 3, we achieved the same high dose intensity as did Rose et al
(1998), Tuxen et al (1997), Seymour et al (1994), and Kavanagh
et al (1995) . It remains to be determined whether further increases
in dose intensity could be reached in patients without severe
haematoxicity if doses were escalated on an individual basis, in
addition to using GM-CSF. However, it is not clear whether still
higher dose intensities are of clinical relevance, particularly since
previous studies do not support a clear relationship between
effective dose intensities and response rates (Table 6) (Garrow et al,
1992; De Wit et al, 1994; Seymour et al, 1994; Kavanagh et al, 1995;
Tuxen et al, 1997; Rose et al, 1998).
When comparing our dose recommendation with that of other
phase I trials, smaller total doses of etoposide can be administered
in schedules with treatment durations of 1–5 days compared to
longer lasting treatments. Data from a randomised trial by Clark
et al (1994), comparing a schedule of 1–5 days to a schedule of 1–
8 days, support these findings (Nissen et al, 1976; Lau et al, 1979;
Table 3 Number of patients (n¼18) with haematological toxicities
(World Health Organization (WHO) grade) over all cycles
WHO grade
Toxicity 0 1 2 3 4
Leucocytes 0 6 5 4 3
Granulocytes 1 5 3 2 7
Thrombocytes 6 3 2 5 2
Haemoglobin 0 3 10 5 0
Table 4 Number of patients (n¼18) with nonhaematological toxicities
(World Health Organization (WHO) grade) over all cycles
WHO grade
Toxicity 0 1 2 3 4
Nausea/vomiting 5 2 7 4 0
Mucositis 9 6 3 0 0
Diarrhoea 9 2 5 1 1
Constipation 11 1 6 0 0
Infection 9 6 1 1 1
Alopecia 0 0 2 16 0
Skin 12 5 1 0 0
Paraesthesia 17 1 0 0 0
Lethargy 16 2 0 0 0
GOT 16 2 0 0 0
Bilirubin 17 1 0 0 0
Creatinine 17 0 1 0 0
Alkaline phosphatase 16 2 0 0 0
GOT¼glutamate oxaloacetic transaminase (Ul
 1), alkaline phosphatase (Ul
 1),
bilirubin (mg%
 1), creatinine (mg%
 1).
Table 5 Response to treatment with etoposide referring to response to
previous platinum treatment (n¼18)
CR PR NC PD NE
Platinum sensitive 4 2 3
Platinum resistant 1 4 2 2
CR¼complete remission; PR¼partial remission; NC¼no change; PD¼progressive
disease; NE¼not evaluable.
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sOgawa et al, 1983; Kimura et al, 1985). Furthermore, two other
phase I trials that explored schedules extended to 21 days
recommended a dosage of 50–75mgm
 2day
 1, which cumula-
tively corresponds to our total dose of 1000mgm
 2 per cycle
(Hainsworth et al, 1989; Noda et al, 1994).
The median response rate in our study was 44%, compared with
median response rates of 26% (range, 0–43%) of other second-line
treatment trials in patients with ovarian cancer (Maskens et al,
1981; Hoskins and Swenerton, 1994; Yasumizu and Kato, 1995;
Kuhn et al, 1996; Rose et al, 1998). Thus, our treatment regimen
can be classified as very effective. Reviewing and comparing the
duration of treatment of all second-line oral etoposide regimens in
patients with ovarian cancer, we observed a marked difference:
One 5-day regimen resulted in a 0% response rate (Maskens et al,
1981), whereas 10- to 21-day regimens resulted in response rates
between 20 and 45% (Hoskins and Swenerton, 1994; Yasumizu and
Kato, 1995; Kuhn et al, 1996; Rose et al, 1998), lending further
support to the superiority of our 10-day design. Another potential
explanation for the high efficacy of our regimen could be related to
an additional cytotoxic effect of GM-CSF, which has been shown to
enhance the number of circulating blood monocytes and their
functional cytotoxic impact (Wing et al, 1989).
In our study, patients with platinum-sensitive disease responded
better than patients with platinum-resistant disease (67 vs 14%)
(Table 5). Previous studies investigating responsiveness to etopo-
side in platinum-resistant patients describe a median response rate
of 20% (range, 0–27%) (Markman et al, 1992; Hoskins and
Swenerton, 1994; Kavanagh et al, 1995; Kuhn et al, 1996; Rose et al,
1998; Alici et al, 2003).Thus, our findings correspond well with
those from other trials, lending further support to a definite,
although modest, activity in this cohort of patients.
We observed a 2-month median time to response when we
evaluated response by objective measurements of tumour dimen-
sion, and a 1.5-month median time when the evaluation also
included additional, serological measurements of CA-125.
Response that occurs early after the start of therapy is important
with regard to symptom palliation and should play a role in the
selection of treatment. The primary reason for the early
tumoricidal effect we observed could be attributed to the 10-day
schedule of our regimen. Clark and Cottier (1992) also demon-
strated a time-to-response advantage of a 10-day regimen as
compared with a 21-day regimen of prolonged oral etoposide in
patients with small-cell lung cancer.
A review of 16 studies performed in 395 evaluable ovarian
cancer patients treated with oral etoposide reveals a clear
relationship between response to oral etoposide and the sequence
of etoposide as first-, second-, third-, fourth-, or fifth-line therapy
(Table 7) (Maskens et al, 1981; Hillcoat et al, 1985; Hansen et al,
Table 6 Overview of clinical studies using oral etoposide in advanced ovarian cancer regarding effective median dose intensity of oral etoposide and
response rate
Schedule of etoposide
Dose escalation of
oral etoposide
planned
Effective median
dose intensity
(mgm
 2week
 1)
Response
rate (%)
Line of
therapy
Garrow et al (1992) 50mgm
 2day
 1  21 days q 4 weeks 175 20 Third
De Wit et al (1994) 50mgm
 2day
 1  21 days q 4 weeks 218 16 Second, third
Kavanagh et al (1995) 50mgm
 2day
 1  21 days q 4 weeks Yes 247 0 Fifth
Rose et al (1998) 50mgm
 2day
 1  21 days q 4 weeks Yes 263 31 Second
Seymour et al (1994) 100mgday
 1  7 days q 3 weeks Yes 267 24 Second, third
Tuxen et al (1997) 170mgm
 2day
 1 5 days q 3 weeks Yes 4283 48 First
Baur et al 75mgm
 2day
 1  10 days q 3 weeks Yes+use of GM-CSF 292 44 Second
Table 7 Relationship of response to oral etoposide and sequence of chemotherapy in patients with advanced ovarian cancer
Grouped according to line of therapy
Author
Line of
therapy
Patients in
each study
(n)
Responding
patients (n)
Response
rate (%) Patients (n)
Responding
patients (n)
Response
rate (%)
Tuxen et al (1997) 1 21 10 48
21 10 48
Maskens et al (1981) 2 18 0 0
Yasumizu and Kato (1995) 2 14 6 43
Kuhn et al (1996) 2 18 4 22
Rose et al (1998) 2 82 25 31
Hoskins and Swenerton (1994) 2 31 8 26
Baur et al 21 6 7 4 4
179 50 28
Markman et al (1992) 3 18 1 6
Garrow et al (1992) 3 15 3 20
Alici et al (2003) 2,3 22 4 18
Hansen et al (1990) 2,3 20 2 10
Seymour et al (1994) 2,3 41 10 24
De Wit et al (1994) 2,3 25 4 16
Hillcoat et al (1985) 2,3,4 23 5 22
Marzola et al 1993 3,4 17 1 6
181 30 17
Kavanagh et al (1995) 5 14 0 0
14 0 0
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s1990; Garrow et al, 1992; Markman et al, 1992; Marzola et al, 1993;
De Wit et al, 1994; Hoskins and Swenerton, 1994; Seymour et al,
1994; Kavanagh et al, 1995; Yasumizu and Kato, 1995; Kuhn et al,
1996; Tuxen et al, 1997; Rose et al, 1998; Alici et al, 2003; our
study). Studies describe reasonable response rates to second- and
third-line therapy. Furthermore, a lack of crossresistance between
taxanes and oral etoposide was found in our study, which was
confirmed by Rose et al (1998), Alici et al (2003), Hoskins and
Swenerton (1994), but not by Kavanagh et al (1995).These data
support the value and acceptability of oral etoposide as a treatment
option in recurring ovarian cancer. The progression-free interval
of a median of 7 months in our trial compared favourably with a
median of 6 months in the GOG study by Rose et al (1998), which,
similar to our study, treated patients in second-line therapy with
chronic oral etoposide. In contrast, a trial using topotecan or
pegylated liposomal doxorubicin as second-line therapy in patients
with recurring ovarian carcinoma reported a median progression-
free interval of only 4 months (Gordon et al, 2001). It is
conceivable that the high response rate in our patients had a
positive influence on the duration of the progression-free interval
among our patients.
Consistant with other studies (Kuhn et al, 1996; Rose et al,
1998), myelotoxicity was the predominant and DLT in our trial.
Yasumizu and Kato (1995), who administered approximately half
the dose of oral etoposide administered by Rose et al (1998),
observed G3 or G4 leucopenia in only 12% of their patients. In our
study, one patient with granulocytopenia died due to sepsis; other
groups have reported similar adverse events (Maskens et al, 1981;
Kuhn et al, 1996; Rose et al, 1998), whereas no patients died in the
trial of Yasumizu and Kato (1995). In sum, because of the wide
intrapatient and interpatient variability in the bioavailability of
oral etoposide, patients who receive oral etoposide must be
carefully monitored for myelosuppression and might need to
discontinue therapy or have their dose modified if they experience
G3 or G4 granulocytopenia (Hande et al, 1993). To improve the
bioavailability of oral etoposide and to optimise the therapeutic
index of etoposide, the prodrug etoposide phosphate can be
administered in a prolonged intraveneous low-volume infusion in
an ambulant setting as an alternative treatment option to oral
etoposide. A further phase I trial consisting of intravenous
etoposide phosphate as continuous infusion over 10 days in
combination with subcutaneous GM-CSF on days 12–19 is needed
to determine the MTD of etoposide phosphate with subcutaneous
GM-CSF for recommendations for future phase II trials in patients
with recurring ovarian cancer.
The deepest granulocyte nadir occurred in the first cycles,
independent of GM-CSF administration or DLs. Moreover, in our
study, the positive influence of GM-CSF on the granulocyte
counts started only on the second cycle and continued onward.
This observation has not been described previously; however,
Paccagnella et al provided a potential explanation in his
investigation of the bone marrow myeloid precursor proliferative
activity in patients with lung cancer treated with chemotherapy
and GM-CSF. They demonstrated a significantly higher rate of
production of the myeloid precursor cells only after the start of the
second treatment cycle (Paccagnella et al, 1993). Thus, the decision
to increase the dose of etoposide at the consecutive DLs in our
study was less likely than we expected to be influenced by
administration of GM-CSF. Thus, in our trial, an increase of dose
intensity achieved by administration of GM-CSF was achieved only
from cycle 2 onward. Weiss et al (1996) suggested an alternative
option for enhancing dose intensities and improving neutrophil
nadirs of the first cycle in a randomised phase I study in which
GM-CSF was administered 5 days before the start of the first
treatment cycle.
In conclusion, we defined the dose of oral etoposide in
combination with GM-CSF s.c. recommended for furture phase
II trials in patients with advanced ovarian cancer pretreated with
platinum. Keeping in mind all the limitations of nonrandomised
small clinical trials, we submit that our 44% response rate is
superior to the rates achieved by similar trials testing second-line
therapy. Moreover, we observed responses in platinum-sensitive
and platinum-resistant patients and no crossresistance with
taxanes. Thus, in sum, our treatment regimen can be highly
recommended for second- and third-line therapy in patients with
recurring ovarian cancer.
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